Tumor Biology

, Volume 37, Issue 12, pp 15635–15641 | Cite as

RETRACTED ARTICLE: Norcantharidin modulates miR-655-regulated SENP6 protein translation to suppresses invasion of glioblastoma cells

  • Zhenxing Zhang
  • Xiaofeng Song
  • Xu Feng
  • Ye Miao
  • Honglei Wang
  • Yang Li
  • He Tian
Original Article


Norcantharidin (NCTD) is currently used as an anticancer drug for the treatment of some malignant cancers. However, whether it may have therapeutic effects on glioblastoma multiforme (GBM) remains unknown. Moreover, the underlying mechanisms have not been completely elucidated. Recently, SUMO-specific protease 6 (SENP6) has been shown as a tumor suppressor in some cancers. Nevertheless, whether it is involved in the pathogenesis of GBM has not been examined. Here, we studied the effects of NCTD on GBM cells. We found that NCTD dose-dependently increased SENP6 protein, but not messenger RNA (mRNA), in GBM cells, resulting in the suppression of cell invasion. Depletion of SENP6 in GBM cells significantly attenuated the NCTD-induced suppression of GBM cell invasion, while overexpression of SENP6 in GBM cells mimicked the effects of NCTD on cell invasion. Moreover, NCTD dose-dependently decreased the levels of microRNA-655 (miR-655), which bound to 3′-UTR of SENP6 mRNA to inhibit its translation. Overexpression of miR-655 decreased SENP6 in GBM cells, while depletion of miR-655 increased SENP6 protein in GBM cells. Taken together, our data demonstrates a previously unappreciated control of NCTD to suppress GBM cell invasion through modulation of miR-655-regulated SENP6 protein translation.


Norcantharidin (NCTD) Glioblastoma multiforme (GBM) SENP6 miR-655 



This work has been supported by the Program for Excellent Talents in Liaoning Province in China (NO. LJQ2013088).

Compliance with ethical standards

All experiments were carried out in strict accordance with the regulations of the Guide for experimental research issued by Liaoning Medical University. The protocol was approved by the Institutional Animal Care and Use Committee of the Liaoning Medical University.

Conflicts of interest



  1. 1.
    Chen J, Huang Q, Wang F. Inhibition of FoxO1 nuclear exclusion prevents metastasis of glioblastoma. Tumour Biol. 2014;35:7195–200.CrossRefPubMedGoogle Scholar
  2. 2.
    Gong J, Zhu S, Zhang Y, Wang J. Interplay of VEGFa and MMP2 regulates invasion of glioblastoma. Tumour Biol. 2014;35:11879–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T, et al. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol. 2014;35:5593–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Li S, Guo W, Gao Y, Liu Y. Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor. Tumour Biol. 2015;36:2607–12.CrossRefPubMedGoogle Scholar
  5. 5.
    Yu X, Jiang Y, Wei W, Cong P, Ding Y, Xiang L, et al. Androgen receptor signaling regulates growth of glioblastoma multiforme in men. Tumour Biol. 2015;36:967–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Yu Y, Ran Q. Nuclear SMAD2 restrains proliferation of glioblastoma. Cell Physiol Biochem. 2015;35:1756–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Kok SH, Hong CY, Kuo MY, Lee CH, Lee JJ, Lou IU, et al. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol. 2003;39:19–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Wang X, Gu Z, Li G, Zhang S, Cao Z, Yang Z, et al. Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa. Oncol Rep. 2014;32:716–22.PubMedGoogle Scholar
  9. 9.
    Shou LM, Zhang QY, Li W, Xie X, Chen K, Lian L, et al. Cantharidin and norcantharidin inhibit the ability of MCF-7 cells to adhere to platelets via protein kinase C pathway-dependent downregulation of α2 integrin. Oncol Rep. 2013;30:1059–66.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Lee YC, Lee LM, Yang CH, Lin AM, Huang YC, Hsu CC, et al. Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells. Oncol Rep. 2013;29:237–43.PubMedGoogle Scholar
  11. 11.
    Xie X, Wu MY, Shou LM, Chen LP, Gong FR, Chen K, et al. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett. 2015;9:837–44.PubMedGoogle Scholar
  12. 12.
    Xie J, Zhang Y, Hu X, Lv R, Xiao D, Jiang L, et al. Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer. Med Oncol. 2015;32:145.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen YJ, Tsai YM, Kuo CD, Ku KL, Shie HS, Liao HF. Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect. Life Sci. 2009;85:642–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhu W, Sun W, Zhang JT, Liu ZY, Li XP, Fan YZ. Norcantharidin enhances TIMP-2 anti-vasculogenic mimicry activity for human gallbladder cancers through downregulating MMP-2 and MT1-MMP. Int J Oncol. 2015;46:627–40.PubMedGoogle Scholar
  15. 15.
    Zhang JT, Fan YZ, Chen CQ, Zhao ZM, Sun W. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol. 2012;40:1501–14.PubMedGoogle Scholar
  16. 16.
    Zhang S, Li G, Ma X, Wang Y, Liu G, Feng L, et al. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal. 2012;24:1803–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang JT, Sun W, Zhang WZ, Ge CY, Liu ZY, Zhao ZM, et al. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-k/MMPs/Ln-5γ2 signaling pathway. BMC Cancer. 2014;14:193.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Li XP, Jing W, Sun JJ, Liu ZY, Zhang JT, Sun W, et al. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo. BMC Cancer. 2015;15:527.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Liu X, Chen W, Wang Q, Li L, Wang C. Negative regulation of TLR inflammatory signaling by the SUMO-deconjugating enzyme SENP6. PLoS Pathog. 2013;9:e1003480.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mukhopadhyay D, Arnaoutov A, Dasso M. The SUMO protease SENP6 is essential for inner kinetochore assembly. J Cell Biol. 2010;188:681–92.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Qian J, Luo Y, Gu X, Wang X. Inhibition of SENP6-induced radiosensitization of human hepatocellular carcinoma cells by blocking radiation-induced NF-κb activation. Cancer Biother Radiopharm. 2013;28:196–200.CrossRefPubMedGoogle Scholar
  22. 22.
    Di Leva G, Croce CM. miRNA profiling of cancer. Curr Opin Genet Dev. 2013;23:3–11.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMedGoogle Scholar
  24. 24.
    He X, Jing Z, Cheng G. MicroRNAs: new regulators of toll-like receptor signalling pathways. BioMed Res Int. 2014;2014:945169.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW, et al. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 2014;8:293–314.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Wang Y, Zang W, Du Y, Ma Y, Li M, Li P, et al. Mir-655 upregulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma. J Transl Med. 2013;11:301.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, et al. Mir-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther. 2014;13:444–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, et al. Mir-655 is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One. 2013;8:e62757.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Coronnello C, Benos PV. Comir: combinatorial microRNA target prediction tool. Nucleic Acids Res. 2013;41:W159–64.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Zhu G, Chen X, Wang X, Li X, Du Q, Hong H, et al. Expression of the RIP-1 gene and its role in growth and invasion of human gallbladder carcinoma. Cell Physiol Biochem. 2014;34:1152–65.CrossRefPubMedGoogle Scholar
  32. 32.
    Shi X, Li X, Li D, Li Y, Song Y, Deng Q, et al. β-hydroxybutyrate activates the NF-κB signaling pathway to promote the expression of pro-inflammatory factors in calf hepatocytes. Cell Physiol Biochem. 2014;33:920–32.CrossRefPubMedGoogle Scholar
  33. 33.
    Lin S, Qiu M, Chen J. IL-4 modulates macrophage polarization in ankylosing spondylitis. Cell Physiol Biochem. 2015;35:2213–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhi X, Tao J, Xiang G, Cao H, Liu Z, Yang K, et al. April induces cisplatin resistance in gastric cancer cells via activation of the NF-κB pathway. Cell Physiol Biochem. 2015;35:571–85.CrossRefPubMedGoogle Scholar
  35. 35.
    Bolshakova A, Magnusson KE, Pinaev G, Petukhova O. Functional compartmentalisation of NF-κB-associated proteins in A431 cells. Cell Biol Int. 2013;37:387–96.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zhenxing Zhang
    • 1
  • Xiaofeng Song
    • 2
  • Xu Feng
    • 1
  • Ye Miao
    • 1
  • Honglei Wang
    • 1
  • Yang Li
    • 1
  • He Tian
    • 2
  1. 1.Department of NeurosurgeryThe First Affiliated Hospital of Liaoning Medical UniversityJinzhouChina
  2. 2.Department of Histology and EmbryologyLiaoning Medical UniversityJinzhouChina

Personalised recommendations